IVF Outcomes, OVARIAN STIMULATION
Conditions
Keywords
follitropin delta, follitropin alfa, menotropins, IVF
Brief summary
The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF). The main questions it aims to answer are: * Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG? * Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes? Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.
Interventions
None listed
Sponsors
Clinique Ovo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Women between 18-45 years included * First ovarian stimulation cycle only * Patients who used mixed protocols combining menotropin and follitropin alfa or delta * Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.
Exclusion criteria
* Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation * Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators * Oocytes donation or fertility preservation cycles
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of utilizable blastocysts per treatment cycle | For IVF performed from January 2018 to December 2024 |
Secondary
| Measure | Time frame |
|---|---|
| Number of stimulation days | For IVF performed from January 2018 to December 2024 |
| Totals doses of rFSH, HP-hMG, and FSH | For IVF performed from January 2018 to December 2024 |
| Costs of rFSH, HP-hMG, and FSH | For IVF performed from January 2018 to December 2024 |
| Number of retrieved oocytes | For IVF performed from January 2018 to December 2024 |
| Number of mature oocytes (MII) | For IVF performed from January 2018 to December 2024 |
| Number of fertilized oocytes (2PN) | For IVF performed from January 2018 to December 2024 |
| Total FSH/ usable blastocysts ratio | For IVF performed from January 2018 to December 2024 |
| Pregnancy rates | For IVF performed from January 2018 to December 2024 |
| Cost per blastocyst | For IVF performed from January 2018 to December 2024 |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATORIsaac-Jacques Kadoch, MD
Clinique Ovo
Outcome results
None listed